+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 30Years - 70Years
All Genders
ID07289477

Phase IIII Study of NouvNeu001 Injection for Safety and Effectiveness in Treating Multiple System Atrophy

Led by iRegene Therapeutics Co., Ltd. · Updated on 2026-04-14

9

Participants Needed

1

Research Sites

195 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety, tolerability, and preliminary effectiveness of a single injection of NouvNeu001, which contains human dopaminergic progenitor cells, in people with Multiple System Atrophy MSA, specifically the Parkinsonian subtype. This Phase IIII clinical trial focuses on patients who have had MSA motor symptoms for no more than five years and whose current treatments do not fully control their symptoms. The study is sponsored by iRegene Therapeutics Co., Ltd. and aims to better understand the risks and potential benefits of this new treatment. Participants will be randomly assigned to one of two groups during the low-dose phase one group will receive a single injection of NouvNeu001 into the putamen region of the brain, while the control group will not receive the injection. The trial is open-label with no masking. The study treatment is administered once, and participants will be followed for one year after the transplantation to assess outcomes. Throughout the 52 weeks after receiving the injection, participants will undergo safety monitoring for adverse events, using standard criteria. Effectiveness will be evaluated by changes in motor symptoms using the Unified Multiple System Atrophy Rating Scale UMSARS and Clinical Global Impression-Severity CGI-S scores at weeks 13, 26, and 52. Brain imaging with DAT PET will also be performed at week 52 to assess dopaminergic metabolism. Participants overall health and ability to walk will be assessed, and adherence to the trial procedures will be closely monitored.

CONDITIONS

Brief Title

A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

Research Team

M

Meng Cai, Ph.D

J

Jing Zhao, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here